About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

359,057 studies
in
219 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 01/26/2021.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 01/26/2021.

Observational Study on Chronic Myeloid Leukemia Patients in Any Phase Treated With Ponatinib (Iclusig®) at Any Dose

Clinicaltrials.gov identifier NCT03933852

Recruitment Status Recruiting

First Posted May 1, 2019

Last update posted September 10, 2020

Study Description

Brief summary:

Additional information is needed to characterize the safety profile of ponatinib as it is used in routine clinical practice in Europe. This observational cohort study will provide a real-life picture of ponatinib use in clinical practice and additional quantification and characterization of adverse events (AEs) and their outcomes in patients with Chronic Myeloid Leukemia in any phase treated with ponatinib.

  • Condition or Disease:Chronic Myeloid Leukemia, Chronic Phase
  • Intervention/Treatment:
  • Phase: N/A
Detailed Description

This study is a multicentre, long-term, prospective and retrospective, observational cohort study of patients who are treated with ponatinib. The study is non-interventional; all Treatment decisions are made at the discretion of the patient's healthcare provider (HCP) and are not mandated by the study design or protocol. A heterogeneous sample of oncology practice sites in Germany (both Hospitals and Field based Haematologists) treating adult patients with Chronic Myeloid Leukemia in any phase using ponatinib will be selected for participation in the study. Eligible, consenting patients initiating treatment with ponatinib will be enrolled into the prospective part of the study. Eligible consenting patients with Chronic Myeloid Leukemia in any Phase that have initiated ponatinib outside clinical trial after its approval in Germany will be enrolled in the retrospective part of the study. Approximately 100 patients will be enrolled from approximately 50 sites. The patient enrolment period is estimated to be approximately two years. Patients who experience an Adverse Event (AE) during treatment or within the 30 days post discontinuation will be followed for 12 months to determine the consequences of the Adverse Event. Data on patient's history, patient's data at baseline, ponatinib treatment, Adverse Events, all medications received, and efficacy measures will be collected during the study in conjunction with routine care visits, anticipated to be approximately every 3 months. Information on any new therapies, including treatment for Chronic Myeloid Leukemia and other medications will be collected during follow-up.

Study Design
  • Study Type: Observational
  • Estimated Enrollment: 100 participants
  • Observational Model: Case-Only
  • Time Perspective: Retrospective
  • Official Title: Observational Study on Chronic Myeloid Leukemia Patients in Any Phase Treated With Ponatinib (Iclusig®) at Any Dose
  • Actual Study Start Date: July 2015
  • Estimated Primary Completion Date: December 2022
  • Estimated Study Completion Date: December 2022
Outcome Measures
  • Primary Outcome Measures: 1. Change in Cytogenetic response [ Time Frame: through study completion, an average of 3 years ]
    Achievement of cytogenetic Response (percentage of Ph+ metaphases)
  • 2. Molecular response [ Time Frame: through study completion, an average of 3 year ]
    BCR-ABL in % (lower is better)
Eligibility Criteria
  • Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
  • Sexes Eligible for Study: All
  • Accepts Healthy Volunteers: No
  • Sampling Method: Non-Probability Sample
  • Study Population: The study will include patients with Chronic Myeloid Leukemia in any phase that are initiating or have initiated treatment with ponatinib and who meet the enrolment criteria and provide informed consent. A group of patients, for whom the decision of starting ponatinib has already been made, but in whom ponatinib has not yet been started, will be identified prospectively and invited to enrol into the study. The study enrolment date is the date the informed consent is signed. An additional group of patients who have received or are receiving ponatinib treatment outside clinical trials will be invited to join the retrospective part of the study.
Criteria

Inclusion Criteria:

- Adult patients (age ≥18 years) with Chronic Myeloid Leukemia in any phase who are
initiating ponatinib monotherapy, or for whom ponatinib monotherapy was initiated
after ponatinib approval in Germany. [The decision to prescribe ponatinib must have
been made prior to enrolment in the study. Patients enrolled in the retrospective part
of the study may or may not be still on ponatinib treatment at the time informed
consent is given. These retrospective patients should have started Treatment after
02.02.2015.].

- Patients who have the ability to understand the requirements of the study, and provide
written informed consent to comply with the study data collection procedures.

- Patients with a minimum life expectancy of 3 months

Exclusion Criteria:

- Patients previously treated with investigational ponatinib (within a clinical trial)

- Patients receiving an investigational agent

- Patients who are pregnant and/or breastfeeding

- Patients who are pregnant and/or breastfeeding

Contacts and Locations
Contacts

Contact: Andreas Hochhaus, Prof. Dr. +49 36419396670 ponderosa@med.uni-jena.de

Locations

Germany
University Hospital Jena
Jena

Sponsors and Collaborators

Prof. Dr. med. Andreas Hochhaus

Investigators

Principal Investigator: Andreas Hochhaus University Hospital Jena

More Information
  • Responsible Party: Prof. Dr. med. Andreas Hochhaus
  • ClinicalTrials.gov Identifier: NCT03933852 History of Changes
  • Other Study ID Numbers: Ponderosa
  • First Posted: May 1, 2019 Key Record Dates
  • Last Update Posted: September 10, 2020
  • Last Verified: September 2020
  • Individual Participant
    Data (IPD) Sharing
    Statement:
  • Plan to Share IPD: No
  • Studies a U.S. FDA-regulated Drug Product: No
  • Studies a U.S. FDA-regulated Device Product: No
  • Additional relevant MeSH terms: Leukemia
    Leukemia, Myeloid
    Leukemia, Myelogenous, Chronic, BCR-ABL Positive